DRUG SUPPLIED DOSE COMMENTS
APREPITANT (FOSAPREPITANT) (Paeds)
(Emend, Emend IV)

Mechanism of action:

Antiemetic, NK1 or Substance P (SP) antagonist



Ref: 163, 349, 409



Last update: 2021-11-08
Capsule: 40 mg, 80 mg, 125 mg

Suspension (BCCH): 20 mg/mL
 Prophylaxis of chemotherapy induced nausea and vomiting (Age > 6 mos)
3 mg/kg/dose (Max 125 mg/dose) PO on day 1 of chemotherapy, then 2 mg/kg/dose (Max 80 mg/dose) PO on days 2 and 3 of chemotherapy

 For prophylaxis of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, who cannot receive dexamethasone, or who have a history of refractory nausea and vomiting with chemotherapy.

Possible adverse effects: hiccups, drowsiness, weakness, loss of appetite, headache, diarrhea or constipation, and increased liver enzymes.

Drug interactions may necessitate dose adjustment of corticosteroids and other medications metabolized by CYP 3A4.

Caution should be used if administering with ifosfamide due to risk of neurotoxicity.



Standard Prescription:

aprepitant__mg PO___ on day(s) __ of chemotherapy

fosaprepitant    _ mg IV x 1 dose on day 1 of chemotherapy